Myxoid Liposarcoma

This is a type of cancer that starts in fat cells. It's called 'myxoid' because it has a jelly-like texture. It's a specific kind of liposarcoma, which is a cancer of fat tissue.

Condition

What people with Myxoid Liposarcoma report

Every report comes from a Lived member, sent anonymously.

Have you tried Radiation Therapy for Myxoid Liposarcoma?

NameHow it went

About Myxoid Liposarcoma

What It Is

Myxoid liposarcoma is a rare cancer that grows in the body's soft tissues, the fat, muscle and connective tissue that support and surround other structures. It is one of several types of liposarcoma, cancers whose cells resemble developing fat cells, and the second most common of them. It usually appears as a deep, painless lump that slowly gets bigger, most often in the thigh, though it can also start elsewhere in the limbs, in the trunk or, less often, inside the abdomen. It tends to affect younger adults than most sarcomas do: in large studies the average age at diagnosis is in the mid-40s, and it occurs in younger people more often than other liposarcomas do. Doctors divide it into a lower-grade form and a higher-grade form called round cell liposarcoma, depending on how much of the tumor is made of densely packed round cells. That distinction matters because it changes the risk of spread and how intensive treatment and follow-up need to be. Most sarcomas spread mainly to the lungs, but myxoid liposarcoma can also spread to other soft tissues, bone and the abdomen.

Causes & Risk Factors

Nearly all myxoid liposarcomas carry a specific genetic change inside the tumor cells. Pieces of two chromosomes trade places and fuse two genes, usually FUS and DDIT3, into one abnormal gene. The protein it makes stops immature fat cells from maturing normally and drives the tumor's growth. This change is so characteristic that laboratories test for it to confirm the diagnosis. Why it happens in a particular person is not known. Some inherited conditions, such as Li-Fraumeni syndrome, and radiation therapy given years earlier raise the risk of soft tissue sarcomas as a group. They have not been shown to explain most cases of this particular type, and for most people with myxoid liposarcoma no cause is found.

How It's Diagnosed

Most soft tissue lumps turn out to be benign, usually lipomas, which are common harmless fatty lumps. A lump that is growing or sits deep in the tissue is usually checked first with ultrasound. An MRI scan then shows the tumor's size and its relationship to nearby muscles, nerves and blood vessels, which is needed to plan surgery and radiation. The diagnosis is made with a biopsy, usually a core needle biopsy in which several thin samples are taken through the skin, often guided by imaging. Ideally a specialist sarcoma team plans it before any operation, because the biopsy path may need to be removed later, and a lump taken out without a planned approach can need more extensive surgery and radiation afterward. A pathologist looks for the tumor's typical appearance and confirms the FUS-DDIT3 gene fusion, or a closely related one, with molecular testing. The report also estimates the share of round cells: more than 5% marks the higher-grade, round cell form. Staging scans then look for spread. Because this type can travel to places other than the lungs, staging usually includes CT scans of the chest, abdomen and pelvis, and many centers add a whole-body MRI, which is better than CT or PET scans at finding small deposits in soft tissue and bone.

Treatment Options

Treatment is planned by a team that includes a sarcoma surgeon, a radiation oncologist and a medical oncologist, ideally at a center that treats sarcoma regularly. For a tumor that has not spread, the goal is to remove it completely with a rim of healthy tissue around it while keeping the limb working well. Amputation is now rarely needed. Myxoid liposarcoma is unusually sensitive to radiation, so radiotherapy is often given in daily sessions over several weeks before surgery. It usually shrinks the tumor, makes a clean removal easier and sharply lowers the chance of the cancer returning in the same place. Radiation given before surgery tends to cause less long-term stiffness, scarring and swelling than radiation given afterward, but it raises the risk of wound-healing problems after the operation. In a trial at specialist centers, a lower-than-standard dose (36 Gy) kept the tumor from returning locally in about 97% of people at 5 years, and some teams now offer it. Some small tumors removed with clear margins may not need radiation at all. Chemotherapy is used more selectively. This tumor responds to chemotherapy better than many sarcomas, and it may be offered for large or round cell tumors to lower the risk of spread, although that evidence comes mostly from observational studies. For disease that has spread or cannot be removed, doxorubicin, an anthracycline chemotherapy, is a usual first choice. Trabectedin (Yondelis), an intravenous chemotherapy approved in the US for advanced liposarcoma after an anthracycline, is particularly useful in this subtype: it holds the disease steady more often than it shrinks it, and it requires regular blood tests during treatment. Clinical trials of newer treatments may also be an option for advanced disease.

What to Expect

Outlook depends mainly on the tumor's size, its round cell content, how deep it lies and whether it was removed with clear margins. In studies of people treated with radiation and surgery, about 87% were alive 5 years later and about 74% at 10 years, and smaller, lower-grade tumors do better than large round cell tumors. These are group averages, not a prediction for any one person. Many people regain good use of the treated limb, but some live with stiffness, swelling, weakness or a wound that was slow to heal, and physical limitations are a common part of life after sarcoma treatment. Worry about recurrence, changes in body image and loss of function are also common, and follow-up care should include support for them. Follow-up lasts years because this cancer can come back late. A typical schedule after higher-grade sarcoma is a visit every 3 to 4 months for the first 2 to 3 years, then twice a year until year 5, then once a year for a total of 8 to 10 years. For myxoid liposarcoma, monitoring is often tailored and may include scans of the abdomen and pelvis or whole-body MRI rather than chest imaging alone, especially after a large or round cell tumor.

When to Seek Help

See a doctor about a soft tissue lump that is getting bigger, sits deep in a muscle or is larger than about 5 cm (2 inches), even if it does not hurt. Most such lumps are benign, but imaging can show which ones need a biopsy, and having that biopsy before any surgery matters if the lump turns out to be a sarcoma. After treatment, contact your care team between scheduled visits if you notice a new lump or swelling, bone pain that does not go away, or a change at the treated site. If you are receiving chemotherapy, call the care team right away for a fever or chills, because chemotherapy can weaken the body's defense against infection.

Questions to Ask Your Doctor

  1. 1.What share of round cells did the pathology report show, and how does that change my treatment and follow-up?
  2. 2.Is my care being planned by a specialist sarcoma team, and should I be seen at a sarcoma center?
  3. 3.Would radiation before surgery help in my case, and what are the trade-offs for wound healing and long-term stiffness?
  4. 4.Do you recommend chemotherapy for me, and what benefit would we realistically expect?
  5. 5.Which scans will I need during follow-up, how often, and for how many years?

Last reviewed • Oct 2026

Educational content, not medical advice.